Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the ...
Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
14h
Hosted on MSNGSK stays optimistic on vaccines amidst US and China woesWhile vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...
Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results